Present study | ||||||
---|---|---|---|---|---|---|
Chromosomal region | Type of alteration | Clinical association | Primary tumor | Recurrence | SPT | Possible candidate genes |
3q21-q26.1 | Gain | Chemoradioresistance | 3q26.1 | 3q26.1 | 3q26.1 | ZIC1, ZIC4 |
6p11-pter | 6p25.3-p25.2 | IRF4, HUS1B, FOXQ1, FOXC1, NQO2 | ||||
6p21.33 | CYP21A2, TNXB, STK19 | |||||
6p12.1 | GFRAL, HMGCLL1, BMP5 | |||||
6p11.2 | PRIM2 | |||||
3q24 | Amplification | 3q24 | 3q24 | 3q24 | - | |
7p11.2-12 | 7p12.1-p11.2 | 7p12.1-p11.2 | EGFR | |||
8p11.1 | 8p11.1 | - | ||||
18p11.3 | 18p11.31-p11.23 | LAMA1, PTPRM | ||||
3p11-pter | Loss | 3p26.1 | 3p26.1 | 3p26.1 | ARL8B | |
3p25.3 | 3p25.3 | 3p25.3 | BRPF1, CIDEC, FANCD2, IRAK2, SEC13, TADA3, VHL | |||
3p24.3 | 3p24.3 | EFHB, RAB5A, C3orf48 | ||||
3p22.3 | 3p22.3 | TRIM71, CCR4 | ||||
3p22.2 | 3p22.2 | 3p22.2 | MLH1 | |||
3p21.31 | 3p21.31 | 3p21.31 | DHX30, CDC25A, ATRIP, TREX1, SHISA5, PFKFB4, NCKIPSD, IP6K2, ARIH2, KLHDC8B, APEH, UBA7, RBM5 | |||
3p14.3 | 3p14.3 | 3p14.3 | APPL1, ARF4, ARHGEF3, DNASE1L3, FLNB, HESX1, IL17RD, LRTM1, WNT5A | |||
3p13 | 3p13 | FOXP1, PPP4R2 | ||||
4p11-pter | 4p16.3 | 4p16.3 | MXD4, TNIP2, NOP14 | |||
4p14 | 4p14 | UGDH, UBE2K | ||||
11q distal | 11q22.3 | 11q22.3 | 11q22.3 | ATM | ||
11q23.3 | 11q23.3 | 11q23.3 | TAGLN, KMT2A, CBL, H2AFX | |||
17p13.1 (TP53) | 17p13.1 | 17p13.1 | 17p13.1 | TP53 | ||
14q distal | Gain | Chemoradiosensitivity | 14q32.33 | 14q32.33 | 14q32.33 | - |
17q | 17q24.1-q24.2 | PRKCA | ||||
17q25.1 | TTYH2 | |||||
22 | 22q11.23 | 22q11.23 | 22q11.23 | GSTT1 | ||
2q31 | Amplification | 2q31.1 | 2q31.1 | - | ||
7q21 | 7q21.3 | 7q21.3 | PEG10 | |||
14q13 | 14q13.3 | 14q13.3 | PAX9 | |||
2q22-q25 | Loss | 2q24.2 | 2q24.2 | MARCH7, CD302 | ||
7q11-q22 | 7q11.22 - q11.23 | 7q11.22 - q11.23 | WBSCR22, CLDN3 |